Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the pH dependency of rat steroid 5α-reductase type II isozyme significantly affects its kinetic properties, including Vmax and Km, suggesting past discrepancies in literature may arise from these pH variances during assays.

In this study, treatment with a 5a-reductase inhibitor increased CD8+ T cell infiltration in benign prostatic hyperplasia tissues, suggesting an impact on inflammatory responses.

This study found that individuals in this Egyptian cohort carrying the leucine (L) allele of the 5-α reductase type II enzyme had a higher risk of developing androgenetic alopecia, which may be associated with oxidative stress.

This research article focuses on nonsteroidal inhibitors of human type I steroid 5-alpha-reductase but reports no new results.

In this study, 4-substituted N-(1,1-dimethylethyl)-3-oxo-4-androstene-17.beta.-carboxamides were synthesized and evaluated in vitro as potential 5 alpha-reductase inhibitors and antiandrogens.

This article reviews the effects of 5 alpha-reductase inhibitors for treating conditions like male pattern baldness and benign prostatic hyperplasia, noting significant DHT reduction but reports no new clinical results.

This study developed a method using HPLC with UV-DAD and ESI-MS detection to identify prohibited substances like minoxidil and hormones in cosmetic products advertised online for hair loss and skin conditions.

This study reports that oral finasteride improved or stabilized hair loss in women with hyperandrogenism but not in postmenopausal women with female pattern hair loss.

This study suggests that beard dermal papilla cells may produce androgen-dependent growth factors that stimulate keratinocyte proliferation, while frontal scalp cells can have an inhibitory effect mediated by TGF-β1.

This article provides a detailed review of minoxidil's pharmacological effects for treating androgenic alopecia but reports no new clinical results.

This article reviews potential mechanisms by which Finasteride might enhance mesenchymal stem cell viability and differentiation post-transplant, suggesting a supportive role in myocardial infarction therapy, yet reports no clinical results.

Dutasteride reduces DHT and improves BPH symptoms more effectively than finasteride.

This article reviews mechanisms by which herbal ingredients may stimulate or inhibit hair growth, and it reports no new clinical findings while suggesting potential for developing hair loss treatments.

People with hair loss have more androgen receptors and enzymes in certain follicles, with men and women showing different patterns.

This study found that both finasteride and dutasteride act as slow, time-dependent inhibitors of steroid 5α-reductase type II, with dutasteride being more efficient, influenced by the enzyme's genetic variants.

This article discusses the structure of the human type II 5 alpha-reductase gene and reports no new experimental results.

This study details the isolation and characterization of the human type II 5 alpha-reductase gene, which may play a role in male pseudohermaphroditism, prostate cancer, and benign prostatic hyperplasia.

In this study, osthenol was identified as a highly potent inhibitor of 5alpha-reductase type I in LNCaP cells, significantly outperforming finasteride.

This review suggests that most mutations in the SRD5A2 gene show no clear genotype-phenotype correlation in 5-α-Reductase deficiency, although mutation location affects severity.

This study found that PNU 157706 is a highly potent inhibitor of human 5α-reductase enzymes, showing a stronger and longer-lasting antiprostatic effect in rats compared to finasteride.

This study found that variations in sleep patterns, free testosterone, and 5-alpha-reductase type 1 activity are associated with changes in sebum excretion in women, which may contribute to variability in acne studies.

In this study of male patients with 46,XY 5α-reductase type 2 deficiency, DHT therapy was effective in achieving penile enlargement during infancy, while testosterone replacement therapy proved more beneficial during puberty, possibly due to increased conversion to DHT.

This study found that the methanolic heartwood extract of Avicennia marina significantly inhibits 5α-reductase type 1, reducing 5α-DHT production by 52% in a cell-based assay with human hair dermal papilla cells.

This study reports that long-term use of finasteride does not affect bone mineral density in men with benign prostatic hyperplasia over a four-year period.

This study found that low-dose finasteride treatment in men with premature androgenetic alopecia decreased levels of 5α-reduced steroids, which may be linked to increased depression symptoms.

This review discusses the development and selectivity of 5 alpha-reductase inhibitors, particularly non-steroidal ones, and reports no new clinical trial results.

This study found that LY320236 is a competitive inhibitor of type I and a non-competitive inhibitor of type II steroid 5alpha-reductase, indicating its potential as a dual inhibitor with differing modes of activity.

This study found that finasteride at 1 mg/day was the most effective dose for treating male pattern hair loss, with similar efficacy to 5 mg/day and better results than lower doses.

This review discusses genetic and nutritional causes of hair loss, highlighting that around 90% of treated men show noticeable hair regrowth with a dual inhibitor, while women's hair loss may improve by correcting iron and l-lysine deficiencies.

This study found that compounds 21–23 and 25 exhibited strong 5α-reductase II inhibition in vitro and significantly reduced rat prostate weight, performing comparably to finasteride.